Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation

AIDS

Volumn 24, Issue 15, 2010, Pages 2375-2380

  Tosini, William ^a,b   Muller, Philippe ^c   Prazuck, Thierry ^d   Benabdelmoumen, Ghania ^b   Peyrouse, Eric ^e   Christian, Bernard ^c   Quertainmont, Yann ^f   Bouvet, Elisabeth ^a,b   Rabaud, Christian ^a,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BICHAT HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d Centre Hospitalier Régional   (France)

^e HÔPITAL SAINTE MARGUERITE   (France)

^f BICÊTRE HOSPITAL   (France)

Author keywords

HIV; HIV prevention; postexposure prophylaxis; side effects; tolerability

Indexed keywords

ATAZANAVIR; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RITONAVIR;

ADULT; ARTICLE; ASTHENIA; BLOOD CELL COUNT; CLINICAL EVALUATION; CLINICAL TRIAL; DIARRHEA; DISEASE TRANSMISSION; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPOSURE; FEMALE; HEALTH BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NAUSEA AND VOMITING; NEPHROLITHIASIS; OCCUPATIONAL EXPOSURE; PATIENT MONITORING; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK ASSESSMENT; SEROCONVERSION; SEXUAL INTERCOURSE; SIDE EFFECT; TABLET FORMULATION; VOMITING;

ADENINE; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; PHOSPHONIC ACIDS; POST-EXPOSURE PROPHYLAXIS; PRACTICE GUIDELINES AS TOPIC; PYRIMIDINONES; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957233991     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833dfad1     Document Type: Article

References (14)

1. Yeni P. French Guidelines for the Medical Management of HIV Infection: Experts Group? Recommendations, 2008 Report, directed by Pr Yéni P. http://www.sante-jeunesse-sports.gouv.fr/ publications-documentation/ publications-documentation-sante/ rapports/rapport-du-groupe-experts-2008-prise- charge-medicalepatients-infectees-par-vih-sous-direction-du-pr-patrick-yeni. html? var-recherche=yeni. [Accessed 22 July 2010].
2. Quirino T, Niero F, Ricci E, Pusterla L, Carradori S, Gabbuti A, et al. HAART tolerability: postexposure prophylaxis in healthcare workers versus treatment in HIV-infected patients. Antivir Ther 2000; 5:195-197.
3. Rabaud C, Bevilacqua S, Beguinot I, Dorvaux V, Schuhmacher H, May T, Canton P. CISIH Nancy Lorraine Champagne-Ardenne, France. Tolerability of postexposure zidovudine R lamivudine R nelfinavir prophylaxis of HIV infection. Clin Infect Dis 2001; 32:1494-1495.
4. Rabaud C, Burty C, Grandidier M, Christian B, Penalba C, Béguinot I, et al. Tolerability of postexposure prophylaxis of HIV infection with the combination of zidovudine/lamivudine and lopinavir/ritonavir (Combivir R Kaletra). Clin Infect Dis 2005; 40:303-305. (Pubitemid 40110678)
5. Burty C, Christian B, Pouaha J, Penalba CH, Chavanet P, Prazuck TH, et al. Tolerability of post-exposure prophylaxis of HIV infection with the combination of lamivudine R tenofovir R atazanavir boosted with by ritonavir (LTA/r) [abstract 92/23O]. Presented at 25th Reunion Interdisciplinaire de Chimiotherapie anti Infectieuse; 2005; Paris.
6. Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 1995; 270:1197-1199; [PMID: 7502044].
7. Tsai CC, Emau P, Follis KE, Beck TW, Benveniste RE, Bischofberger N, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72:4265-4273; [PMID: 9557716]. (Pubitemid 28188732)
8. Otten RA, Smith DK, Adams DR, Pullium JK, Jackson E, Kim CN, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000; 74:9771-9775; [PMID: 11000253].
9. Mayer K, Mimiaga M, Cohen D, Grasso C, Bill R, Vanderwarker R, Fisher A. Tenofovir-based regimens for nonoccupational postexposure prophylaxis (NPEP): improved tolerability and adherence compared to ZDV-based regimens [abstract No. TuPE0432]. XVI International AIDS Conference; 13-18 August 2006; Toronto, Canada.
10. Lugue A, Hulse S, Wang D, Shahzad U, Tanzman E, Antenozzi S, Smith B. Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. Infect Control Hosp Epidemiol 2007; 28:695-701. (Pubitemid 46954756)
11. Absalon J, Uy J, Yang R, Mancini M, McGrath D, for the CASTLE Study Group. Gender-based differences in ARV-naïve patients treated with boosted protease inhibitors: results from the CASTLE study (AI424138) [abstract TUPE0062]. XVII International AIDS Conference (IAC); 3-8 August 2008; Mexico City
12. Moore N, Biour M, Paux G, Loupi E, Begaud B, Boismare F, et al. Adverse drug reaction monitoring: doing it the French way. Lancet 1985; 2:1056-1058. (Pubitemid 16206749)
13. DocoLecompte TH, Garrec A, Thomas L, Trechot PH, May TH, Rabaud CH. Lopinavir-ritonavir (Kaletra) and lithiasis: 7 cases. AIDS 2004; 18:705-706.
14. Lescure FX, Lebrette MG, Han Y, Vincensini JP, Bonnard P, Guessant S, et al. Tolerability of postexposure prophylaxis with the combination of Combivir (CBV)-saquinavir 500-ritonavir (SQV-r) [abstract no. WEPEC006]. Presented at 4th IAS Conference; 22-25 July 2007; Sydney, Australia